Eli Lilly and Company $LLY Shares Bought by KPP Advisory Services LLC

Key Points

• KPP Advisory Services LLC increased its stake in Eli Lilly and Company by 11.6%, now owning 3,535 shares valued at approximately $2.76 million.
• Analysts have set a new consensus price target for Eli Lilly at $938.61, with ratings including one Strong Buy, fifteen Buy, and nine Hold.
• Insider transactions have been notable, with EVP Daniel Skovronsky and Director J Erik Fyrwald purchasing shares, indicating continued confidence in the company's growth and performance.

KPP Advisory Services LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 11.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,535 shares of the company's stock after purchasing an additional 368 shares during the period. KPP Advisory Services LLC's holdings in Eli Lilly and Company were worth $2,756,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. First Citizens Bank & Trust Co. raised its stake in Eli Lilly and Company by 13.0% during the 2nd quarter. First Citizens Bank & Trust Co. now owns 15,513 shares of the company's stock valued at $12,093,000 after acquiring an additional 1,782 shares in the last quarter. Roman Butler Fullerton & Co. raised its stake in shares of Eli Lilly and Company by 2.9% during the second quarter. Roman Butler Fullerton & Co. now owns 8,973 shares of the company's stock valued at $7,293,000 after purchasing an additional 249 shares in the last quarter. Cornerstone Advisory LLC lifted its holdings in Eli Lilly and Company by 0.6% in the second quarter. Cornerstone Advisory LLC now owns 2,591 shares of the company's stock worth $2,020,000 after purchasing an additional 15 shares during the period. Paragon Advisors LLC increased its stake in Eli Lilly and Company by 1.2% during the 2nd quarter. Paragon Advisors LLC now owns 6,447 shares of the company's stock valued at $5,025,000 after buying an additional 78 shares during the period. Finally, Bleakley Financial Group LLC raised its position in shares of Eli Lilly and Company by 18.6% during the 2nd quarter. Bleakley Financial Group LLC now owns 32,739 shares of the company's stock worth $25,521,000 after buying an additional 5,130 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on LLY. Cantor Fitzgerald set a $925.00 target price on Eli Lilly and Company and gave the stock an "overweight" rating in a research report on Thursday, October 9th. HSBC upped their price objective on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Erste Group Bank raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Tuesday, October 14th. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. Finally, Weiss Ratings reiterated a "hold (c+)" rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $938.61.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. This represents a 0.73% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock worth $2,894,841 in the last three months. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Trading Up 1.3%

NYSE:LLY opened at $809.72 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The stock's 50 day moving average price is $762.81 and its 200 day moving average price is $766.75. The company has a market capitalization of $766.36 billion, a PE ratio of 52.85, a P/E/G ratio of 1.14 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the previous year, the company posted $3.92 EPS. The company's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.